Observational studyCancer2025

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).

Massimo Breccia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.